BRPI0307276B8 - uso de um peptídio para prevenção e/ou tratamento de esclerose múltipla - Google Patents
uso de um peptídio para prevenção e/ou tratamento de esclerose múltiplaInfo
- Publication number
- BRPI0307276B8 BRPI0307276B8 BRPI0307276A BR0307276A BRPI0307276B8 BR PI0307276 B8 BRPI0307276 B8 BR PI0307276B8 BR PI0307276 A BRPI0307276 A BR PI0307276A BR 0307276 A BR0307276 A BR 0307276A BR PI0307276 B8 BRPI0307276 B8 BR PI0307276B8
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- prevention
- treatment
- multiple sclerosis
- apitope
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 2
- 102000047918 Myelin Basic Human genes 0.000 abstract 2
- 101710107068 Myelin basic protein Proteins 0.000 abstract 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
peptídios tolerogênicos provenientes da proteína básica da mielina. é fornecido um peptídio que é capaz de se ligar a uma molécula do mhc de classe i ou classe ii sem processamento adicional (i.e. um apítopo) que compreende uma porção da região (131-158) da proteína básica da mielina, em particular é fornecido um apítopo que é selecionado a partir dos seguintes peptídios da proteína básica da mielina: (134-148, 135-149, 136-150, 137-151, 138-152, 139- 153, 140-154). também é fornecido o uso de tal peptídio em uma composição farmacêutica e um método de tratamento e/ou prevenção de uma doença utilizando tal peptídio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0202399.2A GB0202399D0 (en) | 2002-02-01 | 2002-02-01 | Peptide |
| PCT/GB2003/000399 WO2003064464A1 (en) | 2002-02-01 | 2003-01-30 | Tolerogenic peptides from myelin basic protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0307276A BR0307276A (pt) | 2004-12-14 |
| BRPI0307276B1 BRPI0307276B1 (pt) | 2019-08-13 |
| BRPI0307276B8 true BRPI0307276B8 (pt) | 2021-05-25 |
Family
ID=9930251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0307276A BRPI0307276B8 (pt) | 2002-02-01 | 2003-01-30 | uso de um peptídio para prevenção e/ou tratamento de esclerose múltipla |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7071297B2 (pt) |
| EP (1) | EP1474443B1 (pt) |
| JP (1) | JP4559082B2 (pt) |
| KR (1) | KR20040108650A (pt) |
| CN (1) | CN100482685C (pt) |
| AT (1) | ATE477269T1 (pt) |
| AU (1) | AU2003202701B2 (pt) |
| BR (1) | BRPI0307276B8 (pt) |
| CA (1) | CA2473469C (pt) |
| CO (1) | CO5601035A2 (pt) |
| CY (1) | CY1110862T1 (pt) |
| DE (1) | DE60333728D1 (pt) |
| DK (1) | DK1474443T3 (pt) |
| ES (1) | ES2349463T3 (pt) |
| GB (1) | GB0202399D0 (pt) |
| MX (1) | MXPA04007510A (pt) |
| NO (1) | NO332446B1 (pt) |
| NZ (1) | NZ534233A (pt) |
| PL (1) | PL212129B1 (pt) |
| PT (1) | PT1474443E (pt) |
| SI (1) | SI1474443T1 (pt) |
| WO (1) | WO2003064464A1 (pt) |
| ZA (1) | ZA200405546B (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1731912T1 (sl) | 2000-08-21 | 2014-05-30 | Apitope Technology (Bristol) Limited | Postopek izbire peptida |
| EP2134176A4 (en) * | 2007-03-30 | 2012-08-29 | Brigham & Womens Hospital | COMPOUNDS AND METHODS FOR ENHANCING MHC CLASS II THERAPIES |
| AU2008320657B2 (en) | 2007-10-31 | 2013-09-05 | Worg Pharmaceuticals (Zhejiang) Co., Ltd. | Composition |
| DK2488196T3 (en) | 2009-10-12 | 2016-03-14 | Lifebio Lab Llc | A composition for treating multiple sclerosis |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| WO2012021512A2 (en) | 2010-08-10 | 2012-02-16 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| GB201314052D0 (en) | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| KR102717969B1 (ko) | 2014-02-21 | 2024-10-15 | 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) | 글리코타겟팅 치료제 |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| US10046056B2 (en) * | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| CN107249617A (zh) * | 2014-12-24 | 2017-10-13 | 艾匹托普国际股份有限公司 | 组合物 |
| EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| CN108884140B (zh) | 2015-12-03 | 2022-10-25 | 朱诺治疗学股份有限公司 | 修饰的嵌合受体及相关组合物和方法 |
| JP7602702B2 (ja) | 2016-05-03 | 2024-12-19 | ステムセル テクノロジーズ カナダ インコーポレーテッド | 寛容性を誘導するための生体分子の細胞内送達 |
| WO2018127828A1 (en) * | 2017-01-04 | 2018-07-12 | Apitope International Nv | Therapeutic method using tolerogenic peptides |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| CN110317254A (zh) * | 2018-03-28 | 2019-10-11 | 深圳市安群生物工程有限公司 | 人mbp抗原表位肽、抗原、抗体、应用及化学发光试剂盒 |
| EA202092723A1 (ru) | 2018-05-09 | 2021-04-09 | Зе Юниверсити Оф Чикаго | Композиции и способы, касающиеся иммунной толерантности |
| EP3586866A1 (en) | 2018-06-28 | 2020-01-01 | Universität Zürich | Immunodominant proteins and fragments in multiple sclerosis |
| WO2021096972A1 (en) | 2019-11-11 | 2021-05-20 | The Regents Of The University Of California | Polymeric nanoparticles that target liver sinusoidal endothelial cells to induce antigen-specific immune tolerance |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858980A (en) * | 1990-03-30 | 1999-01-12 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
| JPH10500109A (ja) * | 1994-05-10 | 1998-01-06 | イミユロジク・フアーマシユーチカル・コーポレーシヨン | 多発性硬化症のための組成物および治療方法 |
| CZ122697A3 (en) * | 1994-10-25 | 1997-09-17 | Immulogic Pharma Corp | Preparations and methods of treating disseminated sclerosis |
| SI1731912T1 (sl) * | 2000-08-21 | 2014-05-30 | Apitope Technology (Bristol) Limited | Postopek izbire peptida |
-
2002
- 2002-02-01 GB GBGB0202399.2A patent/GB0202399D0/en not_active Ceased
-
2003
- 2003-01-30 PT PT03701612T patent/PT1474443E/pt unknown
- 2003-01-30 SI SI200331890T patent/SI1474443T1/sl unknown
- 2003-01-30 PL PL371549A patent/PL212129B1/pl unknown
- 2003-01-30 BR BRPI0307276A patent/BRPI0307276B8/pt not_active IP Right Cessation
- 2003-01-30 AU AU2003202701A patent/AU2003202701B2/en not_active Ceased
- 2003-01-30 MX MXPA04007510A patent/MXPA04007510A/es active IP Right Grant
- 2003-01-30 DE DE60333728T patent/DE60333728D1/de not_active Expired - Lifetime
- 2003-01-30 DK DK03701612.8T patent/DK1474443T3/da active
- 2003-01-30 EP EP03701612A patent/EP1474443B1/en not_active Expired - Lifetime
- 2003-01-30 CN CNB038030772A patent/CN100482685C/zh not_active Expired - Fee Related
- 2003-01-30 NZ NZ534233A patent/NZ534233A/en not_active IP Right Cessation
- 2003-01-30 JP JP2003564084A patent/JP4559082B2/ja not_active Expired - Fee Related
- 2003-01-30 AT AT03701612T patent/ATE477269T1/de active
- 2003-01-30 WO PCT/GB2003/000399 patent/WO2003064464A1/en not_active Ceased
- 2003-01-30 CA CA2473469A patent/CA2473469C/en not_active Expired - Lifetime
- 2003-01-30 KR KR10-2004-7011906A patent/KR20040108650A/ko not_active Withdrawn
- 2003-01-30 ES ES03701612T patent/ES2349463T3/es not_active Expired - Lifetime
-
2004
- 2004-07-13 ZA ZA2004/05546A patent/ZA200405546B/en unknown
- 2004-07-27 US US10/900,032 patent/US7071297B2/en not_active Expired - Lifetime
- 2004-07-28 NO NO20043210A patent/NO332446B1/no not_active IP Right Cessation
- 2004-08-26 CO CO04083647A patent/CO5601035A2/es not_active Application Discontinuation
-
2010
- 2010-10-27 CY CY20101100972T patent/CY1110862T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0307276B1 (pt) | 2019-08-13 |
| JP2005531497A (ja) | 2005-10-20 |
| CO5601035A2 (es) | 2006-01-31 |
| ES2349463T3 (es) | 2011-01-03 |
| PL371549A1 (en) | 2005-06-27 |
| NZ534233A (en) | 2006-04-28 |
| CA2473469C (en) | 2012-04-24 |
| ZA200405546B (en) | 2005-09-28 |
| PT1474443E (pt) | 2010-10-26 |
| EP1474443A1 (en) | 2004-11-10 |
| DE60333728D1 (de) | 2010-09-23 |
| NO332446B1 (no) | 2012-09-17 |
| DK1474443T3 (da) | 2010-10-18 |
| HK1066551A1 (en) | 2005-03-24 |
| BR0307276A (pt) | 2004-12-14 |
| MXPA04007510A (es) | 2005-07-13 |
| US20050058643A1 (en) | 2005-03-17 |
| CA2473469A1 (en) | 2003-08-07 |
| US7071297B2 (en) | 2006-07-04 |
| JP4559082B2 (ja) | 2010-10-06 |
| ATE477269T1 (de) | 2010-08-15 |
| NO20043210L (no) | 2004-11-01 |
| WO2003064464A1 (en) | 2003-08-07 |
| CN100482685C (zh) | 2009-04-29 |
| EP1474443B1 (en) | 2010-08-11 |
| CN1625564A (zh) | 2005-06-08 |
| CY1110862T1 (el) | 2015-06-10 |
| SI1474443T1 (sl) | 2010-12-31 |
| KR20040108650A (ko) | 2004-12-24 |
| GB0202399D0 (en) | 2002-03-20 |
| AU2003202701B2 (en) | 2009-01-08 |
| PL212129B1 (pl) | 2012-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110862T1 (el) | Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης | |
| PH12013500208A1 (en) | Tolerogenic peptides from myelin basic priotein | |
| BRPI0211200B8 (pt) | peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
| TR200003048T2 (tr) | İnsülinin peptit analoglarının diyabet tedavisi için kullanımı. | |
| EA200600128A1 (ru) | Способ уничтожения раковых клеток (варианты), фармацевтическое средство (варианты) и набор для его осуществления | |
| BRPI0414157A (pt) | polipeptìdeo isolado, ácido nucleico isolado, método para inibir a infecção por vìrus da sìndrome da mancha branca de um crustáceo, e, alimento para um crustáceo | |
| DE3584775D1 (de) | Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken. | |
| DK1082131T3 (da) | Immunoregulator | |
| ATE401400T1 (de) | Antiangiogene peptide zur behandlung oder vorbeugung von endometriose | |
| PT1128841E (pt) | Composicao farmaceutica contendo um antagonista de receptor para o tratamento de disturbios da coagulacao sanguinea | |
| ATE255594T1 (de) | Hepatitis b inhibitoren | |
| WO2006029125A3 (en) | Methods and compositions for treating hypercholesterolemia | |
| MX9700199A (es) | Composiciones de cadena invariante utiles para tratar enfermedades autoinmunes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/08/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/01/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 20A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2707 DE 22-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |